Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Nov 10, 2014; 3(4): 162-170
Published online Nov 10, 2014. doi: 10.5317/wjog.v3.i4.162
Published online Nov 10, 2014. doi: 10.5317/wjog.v3.i4.162
Gynecological malignancies and hormonal therapies: Clinical management and recommendations
Anna Myriam Perrone, Federica Pozzati, Martina Rossi, Martina Procaccini, Lucia Casalini, Erica Santi, Marco Tesei, Pierandrea De Iaco, Oncologic Gynecology Unit, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy
Donatella Santini, Pathology Unit, Sant’Orsola-Malpighi University Hospital, 40138 Bologna, Italy
Claudio Zamagni, Medical Oncology Unit, Sant’Orsola-Malpighi University Hospital, 40138 Bologna, Italy
Author contributions: All authors contributed equally to the work presented in this paper.
Correspondence to: Anna Myriam Perrone, PhD, SSD, Oncologic Gynecology Unit, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. amperrone@libero.it
Telephone: +39-51-6364368 Fax: +39-51-6364392
Received: February 28, 2014
Revised: May 15, 2014
Accepted: September 6, 2014
Published online: November 10, 2014
Processing time: 257 Days and 18.1 Hours
Revised: May 15, 2014
Accepted: September 6, 2014
Published online: November 10, 2014
Processing time: 257 Days and 18.1 Hours
Core Tip
Core tip: In this paper we analyze the role of hormone replacement therapy (HRT) in patients affected by gynecological neoplasms with iatrogenic menopause symptoms. We have analysed more than 70 articles with the aim to evaluate the possibility of using HRT in different gynaecological malignancies related to stage and grade of the neoplasm. The literature shows that the use of HRT is controversial in type I of endometrial cancer, endometrioid type of ovarian cancer, uterine cervix adenocarcinoma and endometrial stroma and leiomyosarcoma.